Oncotelic Therapeutics, Inc. (OTCQB: OTLC), together with Sapu Nano, announced the publication of a peer-reviewed manuscript in the International Journal of Molecular Sciences validating its proprietary Deciparticle nanoparticle platform. The platform was developed through the creation of Sapu003, an investigational intravenous everolimus formulation currently being evaluated in an ongoing Phase 1b clinical trial.
The publication details the platform’s formulation design, scalable cGMP manufacturing process, product stability and preclinical performance. It demonstrates the potential of the Deciparticle platform to enable intravenous delivery of poorly water-soluble therapeutic compounds, a common challenge in drug development. According to the company, the research also supports broader applications for the platform beyond everolimus, including additional hydrophobic drug candidates.
Sapu003 is currently being evaluated in a Phase 1b dose-escalation study in patients with advanced mTOR-sensitive solid tumors. The study aims to assess the drug’s safety, pharmacokinetics and preliminary antitumor activity in combination with exemestane. This clinical progress marks a significant step forward for Oncotelic’s pipeline.
The validation of the Deciparticle platform is important because it addresses a critical bottleneck in oncology: many potent therapeutic compounds are poorly water-soluble, limiting their clinical use. By enabling intravenous delivery, the platform could expand the arsenal of available treatments for cancer patients. The peer-reviewed publication adds scientific credibility to the technology, which may accelerate interest from potential partners or investors.
Oncotelic Therapeutics is a clinical-stage biopharmaceutical company focused on oncology and immunotherapy, targeting high-unmet-need cancers and rare pediatric indications. The company also develops PDAOAI, its proprietary AI platform for drug discovery, lab automation, and AI-assisted GMP manufacturing. Through its relationship with SAPU Bio, an OEB-5 sterile injectable cGMP manufacturing facility, PDAOAI underpins ongoing joint development work with TechForce Robotics.
For more information, visit the company’s newsroom at https://ibn.fm/OTLC.
